ViroPharma shares soar on report of possible buyout offer

John Carroll Another rare disease drug developer is back in the headlines as a rumored takeover target. This time it's ViroPharma, which Bloomberg sources say has drawn the "interest" ...

Roche pharma chief douses hot rumors on Alexion buyout

John Carroll Maybe Roche ($ RHBBY) isn't as interested in Alexion Pharmaceuticals ($ ALXN) as some recent news reports suggest. Roche pharma chief Daniel O'Day told Reuters ...

Ceptaris wins FDA OK for lymphoma gel, clears path to $250M Actelion buyout

John Carroll Malvern, PA-based Ceptaris Therapeutics nailed a delayed FDA approval for Valchlor, a drug designed for the most common form of cutaneous T-cell lymphoma. And the OK clears ...

Amgen bags Onyx Pharma in $10.4B buyout deal

John Carroll Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder left at the table.  FierceBiotech ...

UPDATED: Amgen closing in on $10.5B Onyx buyout

John Carroll Amgen appears close to bagging its biotech prey. After starting out with a $ 120-a-share offer for Onyx, the giant biopharma company appears to have settled on a final ...

M&A watch: Amgen and Onyx haggle over Kyprolis data in stalled buyout talks

Ryan McBride As sources tell Bloomberg, the companies have been stalled in their talks over Amgen's proposed $ 130-per-share acquisition of Onyx because Amgen wants data from an ...

South Africa’s Adcock still in exclusive buyout talks with CFR

Carly Helfand Adcock has received other offers, but its board has deemed them "less compelling" than CFR's. That's good news for CFR, as South Africa's Public ...

Analysts continue to pour cold water on hot Alexion buyout rumors

John Carroll If Roche does actually pull the trigger on a rumored bid for Alexion, you can expect analysts to react with some scathing assessments. FierceBiotech News

Onyx CEO challenges Amgen-only talk in buyout process

Ryan McBride Onyx Pharmaceuticals CEO Tony Coles has held his cards about his company's sales process close to the vest FierceBiotech News

Biotech M&A gossip: Amgen buyout of Onyx could happen soon

Ryan McBride Amgen's highly publicized pursuit of Onyx Pharmaceuticals could end in less than a week, as sources tell Reuters that the two companies could strike an acquisition ...

Celltrion’s manufacturing ops figure in AstraZeneca buyout buzz

John Carroll Rumors are swirling that AstraZeneca may have its sights set on the Korean biosimilars maker, and a buyout would give the British drugmaker–or any of its rivals–an ...

Actelion snags lymphoma drug in $250M buyout deal for Ceptaris

John Carroll Switzerland's Actelion has struck a deal to buy Malvern, PA-based Ceptaris Therapeutics for $ 250 million–provided the FDA comes through with an approval of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS